GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (NYSE:NVO) » Definitions » Tax Provision

NVO (Novo Nordisk AS) Tax Provision : $-3,794 Mil (TTM As of Dec. 2024)


View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk AS Tax Provision?

Novo Nordisk AS's tax provision for the three months ended in Dec. 2024 was $-1,029 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2024 was $-3,794 Mil.

Novo Nordisk AS Tax Provision Historical Data

The historical data trend for Novo Nordisk AS's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Tax Provision Chart

Novo Nordisk AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,797.43 -1,720.56 -1,927.55 -3,071.19 -3,679.11

Novo Nordisk AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -827.68 -949.15 -761.80 -1,054.33 -1,028.77

Novo Nordisk AS Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3,794 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Nordisk AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (NYSE:NVO) » Definitions » Tax Provision
Comparable Companies
OCSE:HLUN A OCSE:STENO LLY JNJ ABBV XSWX:ROG LSE:AZN MRK XSWX:NOVN AMGN PFE GILD XPAR:SAN BMY LSE:GSK TSE:4519 TSE:4568 SHSE:600276 TSE:4578 XTER:BAYN
Traded in Other Exchanges
NONOF:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria
Address
Novo Alle 1, Bagsvaerd, DNK, 2880
Website
https://www.novonordisk.com
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.